A recent study has revealed that Bharat Biotech’s Covaxin produces neutralising titres against all new key variants of COVID-19 including the double mutant strain B.1.617 and B.1.1.7.
In a recent development, a study conducted by Clinical Infectious Diseases in collaboration with National Institute of Virology and Indian Council of Medical Research (ICMR) has revealed that the 'made in India' COVID-19 vaccine, which is Bharat Biotech’s Covaxin, produces neutralizing titres against all new key variants of COVID-19 including the double mutant strain B.1.617 and B.1.1.7.
“A modest reduction in neutralization by a factor of 1.95 was observed against the B.1.617 variant compared to vaccine variant (D614G),”
“No difference in neutralization between B.1.1.7 (first isolated in the UK) and vaccine strain (D614G) was observed,”.
Post a Comment